/C O R R E C T I O N — Veloxis Pharmaceuticals A/S/Sacramento BeeThis subgroup analysis suggests that African Americans experience similar clinical results on LCP-Tacro, once-daily, as with twice-daily tacrolimus and there is evidence to suggest a low…
Some Top-Rated Stocks Set Up As Market Falls – Investor's Business Daily
Some Top-Rated Stocks Set Up As Market FallsInvestor’s Business DailyAlexion Pharmaceuticals (ALXN), whose specialty is treatments for cancer, auto-immunity disorders and transplant rejection, has built a 10-week base. The base shows a correction of ju…
/C O R R E C T I O N — Veloxis Pharmaceuticals A/S/
In the news release, Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro™ in Stable African-American Kidney Transplant Patients at American Transplant Congress …
Knoxville couple undergoing kidney transplant right now at Vanderbilt Hospital
Bride to be giving groom gift of life Today, May 31, 2012.
Intravenous kidney cell transplant experiments raise hope for future human kidney failure treatments
Indiana University School of Medicine scientists have successfully transplanted primary kidney cells intravenously to treat renal failure in rats, pointing the way to a possible future alternative to kidney transplants and expensive dialysis treatments…
Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro™ in Stable African …
HORSHOLM, Denmark, May 31, 2012 /PRNewswire/ — Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests th…
Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of … – MarketWatch (press release)
Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of …MarketWatch (press release)This subgroup analysis suggests that African Americans experience similar clinical results on LCP-Tacro, once-daily, as with twice-daily tacrol…
Veloxis Pharmaceuticals to Present Results from a Patient Subgroup … – PR Newswire (press release)
Veloxis Pharmaceuticals to Present Results from a Patient Subgroup …PR Newswire (press release)… tacrolimus and there is evidence to suggest a lower acute rejection rate. … used for the prevention of transplant allograft rejection after organ tra…
Kidney Drug Helps Transplants & Fights Cancer – dailyRx
Kidney Drug Helps Transplants & Fights CancerdailyRxEarly research using everolimus focused on the key ability to suppress the immune system, allowing kidney transplants to survive. Recent research focuses on the cancer suppressing abilities of the…
Vitamin D may improve heart failure treatment outcomes – Private MD
Private MDVitamin D may improve heart failure treatment outcomesPrivate MDIndividuals who suffer from heart failure may benefit from seeking blood testing to measure their vitamin D levels. New research suggests that this nutrient may play an important…